liver failure
Conditions
Interventions
trimetazidine treatment group:Based on the control group treatment programme and treated with full use of Aspartate ornithine, oral with trimetazidine 20mg / piece, 20mg/ times, 3 times / day, three m
control group:conventional treatment
LOLA group:Based on the control group treatment, L-ornithine-L-aspartate (LOLA) 10 mg IV daily
Sponsors
The First Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Patients have evidence of coagulation abnormality, usually an International Normalized Ratio (INR)=1.5, and/or any degree of mental alteration (encephalopathy); 2. All subjects will be between 18 to 65 years; 3. Hospitalized patients; 4. Informed consent of the patient or nearest relative.
Exclusion criteria
Exclusion criteria: 1. Patients less than age 18 or over 65 years of age; 2. Acute liver failure of pregnancy or the HELLP syndrome; 3. HF thought secondary to intrahepatic malignancy; 4. patients who allergy to any constituents of Trimetazidine; 5. Parkinson disease, parkinsonian symptoms, tremors, restless leg syndrome, other related movement disorders; 6. significant renal function impairment [creatinine clearance rate (GFR) less than 30ml/min]; 7. Females who are lactating or pregnant or those who plan to become pregnant during the study; 8. patients had received artificial liver treatment during the studies; 9. Patients with a diagnosis of myocardial infarct Within 6months; 10. Other factors that are not suitable for the study of the test.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Alanine aminotransferase;Aspartate aminotransferase;INR;Total bilirubin; | — |
Countries
China
Contacts
Public ContactZhujiang Yu
Outcome results
None listed